Product Name:
CDC25A-1
Product Number:
ab-np038-1
Target Full Name: Cell division cycle 25A phosphatase
Target Alias: CDC25M3; M-phase inducer phosphatase 1; MPIP1
Product Type Specific: CDC25A protein phosphatase pan-specific antibody
Antibody Code: NP038-1
Antibody Target Type: Pan-specific
Protein UniProt: P30304
Protein SigNET: CDC25A
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human CDC25A sequence peptide Cat. No.: PE-01AZN99
Antibody Immunogen Sequence: MELGPEPPHRRRLLC
Antibody Immunogen Description: Corresponds to amino acid residues M1 to L14; N-terminus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with recombinant human CDC25A on protein dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Dog | Rat | Mouse.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 58-66 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No immunoreactivity on protein dot blots with recombinant human CDC25B and CDC25C.
Related Product 1: CDC25A (1-14) antibody blocking peptide (Cat. No.: PE-01AZN99)
Related Product 2: CDC25B expression antibody (Cat. No.: AB-NP002-2P)
Related Product 3: CDC25B expression antibody (Cat. No.: AB-NP002-3)
Related Product 4: CDC25B expression antibody (Cat. No.: AB-NP002-4)
Related Product 5: CDC25C expression antibody (Cat. No.: AB-NP003-2)
Related Product 6: CDC25C expression antibody (Cat. No.: AB-NP003-3)
Related Product 7: CDC25A expression antibody (Cat. No.: AB-NP038-2)
Related Product 8: CDC25A expression antibody (Cat. No.: AB-NP038-3)
Scientific Background: CDC25A (Cell Division Cycle 25A) is a 59 kDa protein-tyrosine phosphatase that functions as a dosage-dependent inducer of mitotic progression. It removes inhibitory phosphates from CDKs, promoting G1/S and G2/M phase transitions. It directly dephosphorylates CDK1 (at Thr-14 and Tyr-15) and stimulates its kinase activity. It also dephosphorylates CDK2 in complex with cyclin E. It contains 524 amino acids with a catalytic rhodanese homology domain at the C-terminus and a regulatory N-terminus. CDC25A is activated by PIM1, and inactivated through phosphorylation by checkpoint kinases (Chk1/Chk2). CDC25A is degraded via the ubiquitin-proteasome pathway (mediated by Chk1/Chk2) in response to DNA damage, stopping cell division, which allows for DNA repair and acts as a checkpoint. While often a survival factor, it can act as a pro-apoptotic protein when cleaved by caspases during stress. It has a highly conserved C-terminal catalytic domain and a variable N-terminal regulatory domain. Overexpression of CDC25A is associated with various cancers (e.g., breast cancer) and is associated with poor survival rates in some patients. This description may include information annotated by UniProt and/or Google AI.